0000950123-01-504811.txt : 20011018 0000950123-01-504811.hdr.sgml : 20011018 ACCESSION NUMBER: 0000950123-01-504811 CONFORMED SUBMISSION TYPE: 424B2 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20010730 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SALOMON SMITH BARNEY HOLDINGS INC CENTRAL INDEX KEY: 0000200245 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] IRS NUMBER: 112418067 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B2 SEC ACT: 1933 Act SEC FILE NUMBER: 333-55650 FILM NUMBER: 1692144 BUSINESS ADDRESS: STREET 1: 388 GREENWICH ST STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10013 BUSINESS PHONE: 2128166000 MAIL ADDRESS: STREET 1: SEVEN WORLD TRADE CENTER STREET 2: 29TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10048 FORMER COMPANY: FORMER CONFORMED NAME: PHIBRO CORP DATE OF NAME CHANGE: 19820526 FORMER COMPANY: FORMER CONFORMED NAME: SALOMON INC DATE OF NAME CHANGE: 19920703 424B2 1 y51764e424b2.txt PRICING SUPPLEMENT 1 Filed Pursuant to Rule 424(b)(2) Registration No. 333-55650 THE INFORMATION IN THIS PRICING SUPPLEMENT IS NOT COMPLETE AND MAY BE CHANGED. A REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. THIS PRICING SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS SUPPLEMENT AND PROSPECTUS ARE NOT AN OFFER TO SELL THESE SECURITIES, NOR ARE THEY SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED. SUBJECT TO COMPLETION, DATED JULY 26, 2001 PRICING SUPPLEMENT NO. K00 -- DATED AUGUST -- , 2001 (TO PROSPECTUS DATED FEBRUARY 23, 2001 AND PROSPECTUS SUPPLEMENT DATED MARCH 1, 2001) RULE 424(B)(2) FILE NO. 333-55650 $ -- PRINCIPAL AMOUNT SALOMON SMITH BARNEY HOLDINGS INC. MEDIUM-TERM NOTES, SERIES K (REGISTERED NOTES -- FIXED RATE) -- % NOTES EXCHANGEABLE FOR THE COMMON STOCK OF PFIZER INC., DUE 2008 - The Notes bear interest at the rate of -- % per annum, payable on February -- and August -- of each year, beginning February -- , 2002. - If not previously exchanged by you or called by us, the Notes will mature on August -- , 2008. At maturity you will receive $1,000 in cash for each $1,000 principal amount of Notes you then hold. - EXCHANGE RIGHT Beginning September -- , 2001, you will have the right to exchange each $1,000 principal amount of Notes you then hold for -- shares of Pfizer common stock. - CALL RIGHT Beginning June -- , 2003, upon not less than 30 nor more than 60 days' notice, we may call the Notes, in whole, and not in part, for mandatory redemption on or after August -- , 2003. Following an exercise of our call right, you will receive for each $1,000 principal amount of Notes: - -- shares of Pfizer common stock, if the closing price of that number of shares on the trading day before the notice date is greater than $1,000, or - a call price equal to $1,000 in cash, if the closing price of the -- shares of Pfizer common stock on the trading day before the notice date is less than or equal to $1,000. Your exchange right will cease to be available following any exercise of our call right for the call price. - If you exchange your Notes or if we call the Notes for shares of Pfizer common stock, the value of the shares that you receive may not be greater than the issue price of your Notes. - The Notes will be issued in minimum denominations of $1,000 and integral multiples of $1,000. - We will apply to list the Notes on the American Stock Exchange under the symbol "SPE.A". INVESTING IN THE NOTES INVOLVES A NUMBER OF RISKS. SEE "RISK FACTORS RELATING TO THE NOTES" BEGINNING ON PAGE PS-5. THE NOTES REPRESENT OBLIGATIONS OF SALOMON SMITH BARNEY HOLDINGS INC. ONLY AND DO NOT REPRESENT AN OBLIGATION OF OR INTEREST IN PFIZER INC. OR ANY OF ITS AFFILIATES. PFIZER INC. IS NOT INVOLVED IN ANY WAY IN THIS OFFERING AND HAS NOT AUTHORIZED, SPONSORED OR CONSENTED TO THE ISSUANCE OF THE NOTES. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the Notes or determined that this prospectus, prospectus supplement and pricing supplement is truthful or complete. Any representation to the contrary is a criminal offense.
---------------------------------------------------------------------------------------------------------- PROCEEDS TO SALOMON PRICE TO AGENT'S SMITH BARNEY HOLDINGS INC. PUBLIC(1) COMMISSION (BEFORE EXPENSES)(1) --------- ---------- -------------------------- Per Note........................................... $1,000.00 $10.00 $990.00 Total.............................................. $ -- $ -- $ -- ----------------------------------------------------------------------------------------------------------
(1) Plus accrued interest, if any, from August -- , 2001 to the date of delivery. The Notes are being offered through Salomon Smith Barney Inc., as principal. SALOMON SMITH BARNEY 2 SUMMARY INFORMATION -- Q&A This summary includes questions and answers that highlight selected information from the accompanying prospectus and prospectus supplement and this pricing supplement to help you understand the -- % notes exchangeable for the common stock of Pfizer Inc. You should carefully read the entire prospectus, prospectus supplement and pricing supplement to fully understand the terms of the notes, as well as the principal tax and other considerations that are important to you in making a decision about whether to invest in the notes. You should, in particular, carefully review the section entitled "Risk Factors Relating to the Notes", which highlights a number of risks, to determine whether an investment in the notes is appropriate for you. All of the information set forth below is qualified in its entirety by the more detailed explanation set forth elsewhere in this pricing supplement and the accompanying prospectus supplement and prospectus. WHAT ARE THE NOTES? The notes are a series of unsecured senior debt securities issued by Salomon Smith Barney Holdings Inc. The notes will rank equally with all other unsecured and unsubordinated debt of Salomon Smith Barney Holdings. The notes mature on August -- , 2008 unless they are previously exchanged by you or called by us. You may transfer the notes only in units of $1,000 and integral multiples of $1,000. You will not have the right to receive physical certificates evidencing your ownership except under limited circumstances. Instead, we will issue the notes in the form of a global certificate, which will be held by the Depository Trust Company or its nominee. Direct and indirect participants in DTC will record beneficial ownership of the notes by individual investors. You should refer to the section "Description of the Notes -- Book-Entry System" in the prospectus supplement and the section "Book-Entry Procedures and Settlement" in the prospectus. WILL I RECEIVE INTEREST ON THE NOTES? The notes bear interest at the rate of -- % per annum. We will pay interest in cash semi-annually on each February -- and August -- , commencing on February -- , 2002. WHAT WILL I RECEIVE AT MATURITY OF THE NOTES? At maturity, unless your notes have been previously exchanged by you or called by us, you will receive $1,000 for each $1,000 principal amount of notes you then hold. WHAT WILL I RECEIVE IF I EXERCISE MY EXCHANGE RIGHT? If you exercise your exchange right, you will receive a number of shares of Pfizer common stock equal to the exchange ratio for each $1,000 principal amount of notes you then hold. You will not receive any accrued and unpaid interest on notes you exchange under your exchange right except in the limited circumstances described in "Description of the Notes -- Exchange Right." The exchange ratio will be -- . The exchange ratio will be determined on the date the notes are priced for initial sale to the public. The exchange ratio may be adjusted if a number of events occur, as described under "Description of the Notes -- Dilution Adjustments" in this pricing supplement. In order to exercise your exchange right, you will need to follow the procedures described in "Description of the Notes -- Exchange Right" in this pricing supplement. In lieu of any fractional share of Pfizer common stock otherwise payable in respect of any notes you exchange, you will receive an amount in cash equal to the value of such fractional share of Pfizer common stock, based on the closing price of Pfizer common stock on the date you tender your notes for exchange. PS-2 3 WHAT WILL I RECEIVE IF SALOMON SMITH BARNEY HOLDINGS INC. CALLS THE NOTES? If we exercise our call right, you will receive for each $1,000 principal amount of notes: - a number of shares of Pfizer common stock equal to the exchange ratio if the closing price of that number of shares (as determined by Salomon Smith Barney Inc.) on the trading day before the date we give notice of exercise of our call right is greater than $1,000; or - $1,000 in cash if the closing price of a number of shares of Pfizer common stock equal to the exchange ratio (as determined by Salomon Smith Barney Inc.) on the trading day before the date we give notice of exercise of our call right is less than or equal to $1,000. You will not receive any accrued and unpaid interest on the notes if we call them for redemption in shares of Pfizer common stock. You will receive accrued and unpaid interest on the notes up to and including the call date if we call them for redemption in cash. If we call the notes for redemption in cash, your exchange right will cease to be available beginning on the date we give notice of exercise of our call right. If we call the notes for redemption in shares of Pfizer common stock, you will continue to be able to exercise your exchange right. HOW HAS PFIZER COMMON STOCK PERFORMED HISTORICALLY? We have provided a table showing the high and low sale prices for Pfizer common stock and the cash dividends per share of common stock for each quarter since the first quarter of 1996. You can find this table in the section "Description of the Notes -- Historical Data on the Common Stock of Pfizer Inc." in this pricing supplement. We have provided this historical information to help you evaluate the behavior of Pfizer common stock in recent years. However, past performance is not necessarily indicative of how Pfizer common stock will perform in the future. You should also refer to the section "Risk Factors -- Prior to receiving shares of Pfizer common stock upon your exchange or our call, you will have no rights against Pfizer" in this pricing supplement. WHAT ARE THE TAX CONSEQUENCES OF INVESTING IN THE NOTES? Because the notes will be treated by Salomon Smith Barney Holdings as contingent payment debt obligations of Salomon Smith Barney Holdings, and because by accepting a note each holder agrees to this treatment of the notes, United States holders of a note will be required to include original issue discount for United States federal income tax purposes in gross income on a constant yield basis over the term of the note. This tax OID will be includible in a United States holder's gross income (as ordinary income) over the term of the note even though the amount of tax OID included in income in each year will exceed the semi-annual interest payments to be made on the note prior to maturity or our exercise of our call right or your exercise of your exchange right. The amount of the tax OID is calculated based in part on an assumed amount payable upon exchange or redemption. This assumed amount is neither a prediction nor guarantee of the actual yield of, or payment to be made in respect of, a note or whether we will exercise our call right or you will exercise your exchange right. If the amount we actually pay upon exchange or redemption is, in fact, less than this assumed amount, or if neither Salomon Smith Barney Holdings nor a United States holder exercises, respectively, the call right or the exchange right, then a United States holder will have recognized taxable income in periods prior to exchange, redemption or maturity that exceeds that holder's economic income from holding the note during such periods (with an offsetting ordinary loss upon exchange or redemption or at maturity). If we exercise our call right, or a United States holder exercises its exchange right or otherwise disposes of the note prior to maturity, the United States holder will be required to treat any gain recognized upon the disposition of the note as ordinary income (rather than capital gain). You should refer to "Certain United States Federal Income Tax Considerations" in this pricing supplement and "United States Federal Income Tax Considerations" in the prospectus supplement. PS-3 4 WILL THE NOTES BE LISTED ON A STOCK EXCHANGE? We will apply to list the notes on the AMEX under the symbol "SPE.A". You should be aware that the listing of the notes on the AMEX will not necessarily ensure that a liquid trading market will be available for the notes. WHAT IS THE ROLE OF SALOMON SMITH BARNEY HOLDINGS' SUBSIDIARY, SALOMON SMITH BARNEY INC.? Our subsidiary, Salomon Smith Barney Inc., is the manager for the offering and sale of the notes. After the initial offering, Salomon Smith Barney Inc. and/or other of our broker-dealer affiliates intend to buy and sell notes to create a secondary market for holders of the notes, and may engage in other activities described in the section "Plan of Distribution" in the accompanying prospectus supplement. However, neither Salomon Smith Barney Inc. nor any of these affiliates will be obligated to engage in any market-making activities, or continue them once it has started. CAN YOU TELL ME MORE ABOUT SALOMON SMITH BARNEY HOLDINGS? Salomon Smith Barney Holdings is a holding company that provides investment banking, securities and commodities trading, brokerage, asset management and other financial services through its subsidiaries. Salomon Smith Barney Holdings is a subsidiary of Citigroup Inc., a diversified financial services holding company. Salomon Smith Barney Holdings' ratios of earnings to fixed charges (Salomon Smith Barney Holdings has no outstanding preferred stock) since 1996 are as follows:
THREE MONTHS ENDED YEAR ENDED DECEMBER 31, MARCH 31, ------------------------------------ 2001 2000 1999 1998 1997 1996 ------------ ---- ---- ---- ---- ---- Ratio of earnings to fixed charges........ 1.32 1.32 1.46 1.11 1.17 1.37
DOES ERISA IMPOSE ANY LIMITATIONS ON PURCHASES OF THE NOTES? An employee benefit plan subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA) or a plan that is subject to Section 4975 of the Internal Revenue Code, including individual retirement accounts, individual retirement annuities or Keogh plans, or any entity the assets of which are deemed to be "plan assets" under ERISA regulations, will be permitted to purchase, hold and dispose of the notes only on the condition that such plan or entity makes the deemed representation that its purchase, holding and disposition of the notes will not constitute a prohibited transaction under ERISA or Section 4975 of the Internal Revenue Code. Government plans subject to any substantially similar law will also be subject to this condition. ARE THERE ANY RISKS ASSOCIATED WITH MY INVESTMENT? Yes, the notes are subject to a number of risks. Please refer to the section "Risk Factors Relating to the Notes" in this pricing supplement. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE The following documents, filed by us with the SEC pursuant to Section 13 of the Securities Exchange Act of 1934 (File No. 1-4346), are incorporated herein by reference: (i) Annual Report on Form 10-K for the year ended December 31, 2000, (ii) Quarterly Report on Form 10-Q for the quarter ended March 31, 2001 and (iii) Current Reports on Form 8-K filed on January 17, 2001, February 2, 2001, February 28, 2001, March 6, 2001 (as amended March 29, 2001), March 23, 2001, April 17, 2001, May 30, 2001 and July 17, 2001. You should refer to "Prospectus Summary -- Where You Can Find More Information" in the accompanying prospectus. These documents may also be accessed electronically by means of the SEC's home page on the world wide web on the internet at "http://www.sec.gov." PS-4 5 RISK FACTORS RELATING TO THE NOTES An investment in the notes entails significant risks not associated with similar investments in a conventional debt security, including, among other things, fluctuations in the market price of Pfizer common stock, and other events that are difficult to predict and beyond our control. YOU WILL NOT PARTICIPATE IN THE APPRECIATION OF PFIZER COMMON STOCK UNLESS IT APPRECIATES SIGNIFICANTLY FROM ITS VALUE ON AUGUST -- , 2001 The notes offer you less opportunity to participate in any appreciation of Pfizer common stock than does an investment in Pfizer common stock because you will not participate in any appreciation in the price of Pfizer common stock unless you exchange or we call the notes and the price of Pfizer common stock appreciates approximately -- % from August -- , 2001 to the date the exchange is effected (or, if we call the notes, on the trading day before the date we give notice). YOU WILL NOT PARTICIPATE IN THE FIRST -- % OF ANY APPRECIATION OF PFIZER COMMON STOCK Even if the price of Pfizer common stock appreciates from August -- , 2001 and you exchange or we call the notes, you will not participate in approximately the first -- % of the appreciation in the price of Pfizer common stock from its price on August -- , 2001. THE VALUE OF THE SHARES OF PFIZER COMMON STOCK YOU RECEIVE UPON OUR CALL OF THE NOTES MAY DECLINE DURING THE PERIOD FROM THE EXERCISE OF OUR CALL RIGHT TO THE DATE OF REDEMPTION Following any exercise of our call right that results in delivery of shares of Pfizer common stock (rather than payment of the call price in cash) up to and including the date on which the redemption is effected, you are subject to the risk of decline in the price of Pfizer common stock, and therefore a reduction in the value of the shares you receive upon redemption. Unlike most conventional convertible debt securities, this risk may cause you to receive shares with a value less than the principal amount of your notes in certain circumstances. Although you can limit the risk of a decline in the price of Pfizer common stock by immediately exercising your exchange right on the date we provide notice of a call, you cannot entirely eliminate this risk on the date we provide notice of a call. THE YIELD ON THE NOTES MAY BE LOWER THAN THE YIELD ON A STANDARD DEBT SECURITY OF COMPARABLE MATURITY The annual interest rate on the notes will be only -- %. As a result, if the price of Pfizer common stock over the term of the notes is less than, equal to or only slightly greater than a price equal to $1,000 divided by the exchange ratio (a price that represents a -- % appreciation in the price of Pfizer common stock from its price on August -- , 2001), you will receive an amount of shares or cash upon exchange or redemption with a value that is equal to or slightly greater than the principal amount of your notes and the effective yield on your notes will be less than that which would be payable on a conventional fixed-rate, non-callable debt security of Salomon Smith Barney Holdings of comparable maturity. PRIOR TO RECEIVING SHARES OF PFIZER COMMON STOCK UPON YOUR EXCHANGE OR OUR CALL, YOU WILL NOT RECEIVE DIVIDENDS PAID ON PFIZER COMMON STOCK Your return on the notes will not reflect the return you would realize if you actually owned shares of Pfizer common stock and received any dividends paid on those shares because the notes do not entitle you to receive those dividends. THE PRICE AT WHICH YOU WILL BE ABLE TO SELL YOUR NOTES PRIOR TO MATURITY WILL DEPEND ON A NUMBER OF FACTORS AND MAY BE SUBSTANTIALLY LESS THAN YOU ORIGINALLY INVEST We believe that the value of the notes in the secondary market will be affected by supply and demand for the notes, the value of Pfizer common stock and a number of other factors. Some of these factors are interrelated in complex ways. As a result, the effect of any one factor may be offset or magnified by the PS-5 6 effect of another factor. The following paragraphs describe what we expect to be the impact on the value of the notes of a change in a specific factor, assuming all other conditions remain constant. Pfizer common stock price. We expect that the market value of the notes at any time may be affected by changes in the price of Pfizer common stock. However, changes in the price of Pfizer common stock may not always be reflected, in full or in part, in the market value of the notes. Increases in the price of Pfizer common stock of less than -- % over the price of Pfizer common stock on the day the notes were priced for initial sale to the public may not be fully reflected in the trading price of the notes because holders of the notes would not participate in those increases upon their exchange or our call for Pfizer common stock. If you choose to sell your notes when the price of Pfizer common stock is below the price of Pfizer common stock on the day the notes were priced for initial sale to the public, you may receive less than the amount you originally invested. The value of Pfizer common stock will be influenced by Pfizer's results of operations and by complex and interrelated political, economic, financial and other factors that can affect the capital markets generally and the market segment of which Pfizer is a part. Our hedging activities in Pfizer common stock, the issuance of securities similar to the notes and other trading activities by Salomon Smith Barney Holdings, its affiliates and other market participants can also affect the price of Pfizer common stock. Volatility of Pfizer common stock. Volatility is the term used to describe the size and frequency of market fluctuations. The price of Pfizer common stock has been highly volatile in recent months. See "Historical Data on the Common Stock of Pfizer Inc." in this pricing supplement. As a result of the volatility of Pfizer common stock, the market value of the notes may decrease. Call feature. Our ability to call the notes prior to their maturity date is likely to limit their value. We believe that if we did not have the right to call the notes, their value could be significantly different. Interest rates. We expect that the market value of the notes will be affected by changes in U.S. interest rates. In general, if U.S. interest rates increase, the value of the notes may decrease, and if U.S. interest rates decrease, the value of the notes may increase. Time remaining to maturity. As a result of a "time premium," the notes may trade at a value above that which would be expected based on the level of interest rates and the price of Pfizer common stock the longer the time remaining to maturity. A "time premium" results from expectations concerning the price of Pfizer common stock during the period prior to the maturity of the notes. However, as the time remaining to the maturity of the notes decreases, this time premium may decrease, decreasing the market value of the notes. Dividend yield. If the dividend yield on Pfizer common stock increases, we expect that the value of the notes may decrease, since the value of any shares or cash you will receive upon your exchange or our call will not reflect the value of such dividend payments. Salomon Smith Barney Holdings' credit ratings, financial condition and results. Actual or anticipated changes in our credit ratings, financial condition or results may affect the value of the notes. Economic conditions and earnings performance of Pfizer. The general economic conditions and earnings results of Pfizer and real or anticipated changes in those conditions or results may affect the value of the notes. We want you to understand that the impact of one of the factors specified above, such as an increase in interest rates, may offset some or all of any change in the value of the notes attributable to another factor, such as an increase in the value of Pfizer common stock. In general, assuming all relevant factors are held constant, we expect that the effect on the value of the notes of a given change in most of the factors listed above will be less if it occurs later in the term of the notes than if it occurs earlier in the term of the notes. PS-6 7 THE HISTORICAL PERFORMANCE OF PFIZER COMMON STOCK IS NOT AN INDICATION OF THE FUTURE PERFORMANCE OF PFIZER COMMON STOCK The historical price of Pfizer common stock is not an indication of the future performance of Pfizer common stock during the term of the notes. Changes in the price of Pfizer common stock will affect the trading price of the notes, but it is impossible to predict whether the price of Pfizer common stock will rise or fall. PRIOR TO RECEIVING SHARES OF PFIZER COMMON STOCK UPON YOUR EXCHANGE OR OUR CALL, YOU WILL HAVE NO RIGHTS AGAINST PFIZER Prior to receiving shares of Pfizer common stock upon your exchange or our call, you will have no rights against Pfizer even though: - you will receive Pfizer common stock upon your exchange or, under some circumstances, our call; and - the market value of the notes is expected to depend primarily on the value of Pfizer common stock. Pfizer is not in any way involved in this offering and has no obligations relating to the notes or to holders of the notes. In addition, you will only have voting rights with respect to Pfizer common stock if you receive shares following your exchange or our call. THE VALUE OF THE PFIZER COMMON STOCK YOU RECEIVE UPON YOUR EXCHANGE OR OUR CALL MAY BE REDUCED UNDER SOME CIRCUMSTANCES IF PFIZER COMMON STOCK IS DILUTED BECAUSE THE EXCHANGE RATIO WILL NOT BE ADJUSTED FOR ALL EVENTS THAT DILUTE PFIZER COMMON STOCK The exchange ratio is subject to adjustment for a number of events arising from stock splits and combinations, stock dividends, a number of other actions of Pfizer that modify its capital structure and a number of other transactions involving Pfizer, as well as for the liquidation, dissolution or winding up of Pfizer. You should refer to the section "Description of the Notes -- Dilution Adjustments" below. The exchange ratio will not be adjusted for other events that may reduce the price of Pfizer common stock, such as offerings of common stock for cash or in connection with acquisitions. Because of the relationship of the value of any shares of Pfizer common stock you receive upon your exchange or our call to the then-current price of Pfizer common stock, these other events may reduce the value of those shares, or determine whether you receive shares in the event we call the notes. YOU MAY NOT BE ABLE TO SELL YOUR NOTES IF AN ACTIVE TRADING MARKET FOR THE NOTES DOES NOT DEVELOP There is currently no secondary market for the notes. Salomon Smith Barney Inc. currently intends, but is not obligated, to make a market in the notes. Even if a secondary market does develop, it may not be liquid and may not continue for the term of the notes. If the secondary market for the notes is limited, there may be few buyers should you choose to sell your notes prior to maturity. SALOMON SMITH BARNEY INC., AN AFFILIATE OF SALOMON SMITH BARNEY HOLDINGS, IS THE CALCULATION AGENT, WHICH COULD RESULT IN A CONFLICT OF INTEREST Because Salomon Smith Barney Inc., which is acting as the calculation agent for the notes, is an affiliate of ours, potential conflicts of interest may exist between the calculation agent and you, including with respect to certain determinations and judgments that the calculation agent must make in determining amounts due to you. PS-7 8 BECAUSE PURCHASES AND SALES BY AFFILIATES OF SALOMON SMITH BARNEY HOLDINGS MAY REDUCE THE PRICE OF PFIZER COMMON STOCK, THE VALUE OF THE SHARES OF PFIZER COMMON STOCK YOU RECEIVE UPON YOUR EXCHANGE OR OUR CALL OR THE PRICE YOU RECEIVE IF YOU SELL YOUR NOTES MAY BE REDUCED Salomon Smith Barney Holdings' affiliates, including Salomon Smith Barney Inc., may from time to time buy or sell shares of Pfizer common stock or derivative instruments relating to Pfizer common stock for their own accounts in connection with their normal business practices. These transactions could affect the value of Pfizer common stock. Salomon Smith Barney Inc. or an affiliate may enter into a swap agreement with one of Salomon Smith Barney Holdings' other affiliates in connection with the sale of the notes and may earn additional income as a result of payments pursuant to the swap or related hedge transactions. THE PAYMENTS YOU RECEIVE ON THE NOTES WILL LIKELY BE DELAYED OR REDUCED IN THE EVENT OF A BANKRUPTCY OF SALOMON SMITH BARNEY HOLDINGS If a bankruptcy proceeding is commenced in respect of Salomon Smith Barney Holdings, the claim of a holder of notes may be limited and any recovery will likely be substantially delayed. PS-8 9 DESCRIPTION OF THE NOTES GENERAL The description in this pricing supplement of the particular terms of the -- % Notes Exchangeable for the Common Stock of Pfizer Inc., Due 2008 supplements, and to the extent inconsistent therewith replaces, the descriptions of the general terms and provisions of the registered notes set forth in the accompanying prospectus and prospectus supplement. INTEREST The Notes will bear interest at a rate equal to -- % per annum, calculated on the basis of a 360-day year of twelve 30-day months. The interest payment dates with respect to the Notes are February -- and August -- of each year, commencing February -- , 2002. The record date with respect to any interest payment date will be the date (whether or not a Business Day) immediately preceding the interest payment date. "Business Day" means any day that is not a Saturday, a Sunday or a day on which the American Stock Exchange or banking institutions or trust companies in the City of New York are authorized or obligated by law or executive order to close. PAYMENT AT MATURITY At maturity, unless your Notes have been previously exchanged by you or called by us, you will receive $1,000 for each $1,000 principal amount of Notes you then hold. EXCHANGE RIGHT Beginning on September -- , 2001, you will have the right, by completing the Official Notice of Exchange attached as Exhibit A to this pricing supplement and delivering that notice to both the calculation agent and the paying agent for the Notes no later than 11:00 a.m. New York City time on any Trading Day, to exchange each $1,000 principal amount of Notes you then hold for a number of shares of Pfizer common stock equal to the Exchange Ratio. You will be able to exercise your exchange right through and including the Trading Day prior to the earliest of: - maturity; - if we call the Notes for redemption in shares of Pfizer common stock, as described below, the date specified in our notice of redemption, which we refer to as the "Call Date"; and - if we call the Notes for redemption in cash, as described below, the Trading Day on which we give notice of our exercise of our call right, which we refer to as the "Call Notice Date". We will deliver the shares to you three Business Days after the date you deliver a valid Official Notice of Exchange (the "Exchange Date"), as long as the paying agent has received delivery of your Notes on the Exchange Date. We will not pay accrued and unpaid interest on Notes that you exchange under your exchange right. Notwithstanding the foregoing, we will pay you accrued interest up to and including the earlier of the Exchange Date and August -- , 2003, if: - you exercise your exchange right after we call the Notes for mandatory redemption in shares of Pfizer common stock; - the Call Notice Date is on or before August -- , 2003; and - the Call Date is on or after August -- , 2003. PS-9 10 The Exchange Ratio is expected to be -- . The actual Exchange Ratio will be determined on the date the Notes are priced for initial sale to the public. The Exchange Ratio may be adjusted as described under "Description of the Notes -- Dilution Adjustments". A "Trading Day" means a day on which (1) Pfizer common stock is not suspended from trading on any national or regional securities exchange, securities market or association or over-the-counter market at the close of business and (2) Pfizer common stock has traded at least once on the national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the security. CALL RIGHT Beginning on June -- , 2003, upon not less than 30 nor more than 60 days' notice to holders of the Notes in the manner described below, we may call the Notes, in whole, and not in part, for mandatory redemption on or after August -- , 2003. Following an exercise of our call right, you will receive for each $1,000 principal amount of Notes: - a number of shares of Pfizer common stock equal to the Exchange Ratio, if the Closing Price of that number of shares on the Trading Day immediately preceding the Call Notice Date, as determined by the calculation agent, is greater than $1,000, or - an amount in cash equal to $1,000 (the "Call Price"), if the Closing Price of a number of shares of Pfizer common stock equal to the Exchange Ratio on the Trading Day immediately preceding the Call Notice Date, as determined by the calculation agent, is less than or equal to the Call Price. Once we call the Notes, unless you have already exercised your exchange right, we will deliver to you shares of Pfizer common stock or pay you the Call Price in cash, as the case may be: - three Business Days after the Call Date specified in our notice of mandatory redemption, if we deliver to you shares of Pfizer common stock; or - on the Call Date, if we pay you the Call Price. We will not pay accrued and unpaid interest on the Notes if we call them for mandatory redemption for Pfizer common stock. We will pay accrued and unpaid interest up to and including the Call Date on the Notes if we call them for mandatory redemption in cash at the Call Price. If we call the Notes for redemption in cash at the Call Price, your exchange right will cease to be available beginning on the Call Notice Date. If we call the Notes for redemption in shares of Pfizer common stock, you will continue to be able to exercise your exchange right. Call notices and other notices will be published in a leading daily newspaper in the City of New York, which is expected to be The Wall Street Journal. Notwithstanding the foregoing, so long as the Notes are represented by global securities and are held on behalf of the depositary, any such notice may, at our option in lieu of publication, be given by delivery to the depositary, in which event such notice shall be deemed to have been given to holders of the Notes on the seventh Trading Day after the day on which such notice is delivered. DELIVERY OF SHARES We may satisfy our obligation to deliver shares of Pfizer common stock under the Notes at any time by causing our affiliate, Salomon Smith Barney Inc., to deliver the shares to the paying agent through the facilities of DTC. If we do so, the paying agent will in turn be obligated to deliver the shares to holders of the Notes. We will not deliver fractional shares of Pfizer common stock. In lieu of fractional shares, holders will instead receive a cash payment equal to the product of the fractional amount of a single share of Pfizer common stock and the Closing Price per share of Pfizer common stock on the applicable Exchange Date or Call Date, as the case may be. If physical or book-entry delivery of shares of Pfizer common stock PS-10 11 cannot be made at any time as required by the terms of the Notes, we will pay holders of the Notes an amount in cash equal to the value of the shares of Pfizer common stock due at the relevant time and any cash required to be delivered as a result in lieu of fractional shares. The "Closing Price" of Pfizer common stock on any date of determination will be the daily closing sale price or, if no closing sale price is reported, the last reported sale price of a share of Pfizer common stock as reported on the New York Stock Exchange. If Pfizer common stock is not quoted on the New York Stock Exchange on that date of determination, the Closing Price will be the last reported sale price as reported in the composite transactions for the principal U.S. exchange on which Pfizer common stock is listed. If Pfizer common stock is not listed on a U.S. national or regional securities exchange, the Closing Price will be the last quoted bid for Pfizer common stock in the over-the-counter market as reported by the National Quotation Bureau or a similar organization. PAYING AGENT, TRUSTEE AND CUSIP Citibank, N.A. will serve as Paying Agent and Registrar for the Notes and will also hold the global security representing the Notes as custodian for DTC. Bank One Trust Company, N.A., as successor trustee under an indenture dated as of December 1, 1988, as amended from time to time, will serve as Trustee for the Notes. The CUSIP number for the Notes is -- . DILUTION ADJUSTMENTS The Exchange Ratio will be subject to adjustment from time to time in certain situations. Any of these adjustments could have an impact on the amount you will receive if you exchange or we call the Notes, and on whether you will receive shares of Pfizer common stock in the event we call the Notes. Salomon Smith Barney Inc., as calculation agent, will be responsible for the effectuation and calculation of any adjustment described in this section and will furnish the trustee with notice of any adjustments. If Pfizer, after the closing date: (1) pays a stock dividend or makes a distribution with respect to its common stock in shares of the stock; (2) subdivides or splits the outstanding shares of its common stock into a greater number of shares; (3) combines the outstanding shares of its common stock into a smaller number of shares; or (4) issues by reclassification of shares of its common stock any shares of other common stock of Pfizer; then, in each of these cases, the Exchange Ratio will be multiplied by a dilution adjustment equal to a fraction, the numerator of which will be the number of shares of Pfizer common stock outstanding immediately after the event, or, in the case of a reclassification referred to in (4) above, the number of shares of other common stock of Pfizer, and the denominator of which will be the number of shares of Pfizer common stock outstanding immediately before the event. If Pfizer, after the closing date, issues, or declares a record date in respect of an issuance of, rights or warrants to all holders of its common stock entitling them to subscribe for or purchase its common stock at a price per share less than the Then-Current Market Price of the common stock, other than rights to purchase common stock pursuant to a plan for the reinvestment of dividends or interest, then, in each case, the Exchange Ratio will be multiplied by a dilution adjustment equal to a fraction, the numerator of which will be the number of the shares of common stock outstanding immediately before the adjustment is effected, plus the number of additional shares offered for subscription or purchase pursuant to the rights or warrants, and the denominator of which will be the number of shares of common stock outstanding immediately before the adjustment is effected by reason of the issuance of the rights or warrants, plus the number of additional shares of common stock which the aggregate offering price of the total number of PS-11 12 shares of common stock offered for subscription or purchase pursuant to the rights or warrants would purchase at the Then-Current Market Price of the common stock, which will be determined by multiplying the total number of shares so offered for subscription or purchase by the exercise price of the rights or warrants and dividing the product obtained by the Then-Current Market Price. To the extent that, after the expiration of the rights or warrants, the shares of common stock offered thereby have not been delivered, the Exchange Ratio will be further adjusted to equal the Exchange Ratio which would have been in effect had the adjustment for the issuance of the rights or warrants been made upon the basis of delivery of only the number of shares of common stock actually delivered. If Pfizer, after the closing date, declares or pays a dividend or makes a distribution to all holders of the common stock of any class of its capital stock, the capital stock of one or more of its subsidiaries, evidences of its indebtedness or other non-cash assets, excluding any dividends or distributions referred to in the above paragraph, or issues to all holders of its common stock rights or warrants to subscribe for or purchase any of its or one or more of its subsidiaries' securities, other than rights or warrants referred to in the above paragraph, then, in each of these cases, the Exchange Ratio will be multiplied by a dilution adjustment equal to a fraction, the numerator of which will be the Then-Current Market Price of one share of the common stock, and the denominator of which will be the Then-Current Market Price of one share of the common stock, less the fair market value (as determined by a nationally recognized independent investment banking firm retained for this purpose by Salomon Smith Barney Holdings, whose determination will be final) as of the time the adjustment is effected of the portion of the capital stock, assets, evidences of indebtedness, rights or warrants so distributed or issued applicable to one share of common stock. Notwithstanding the foregoing, in the event that, with respect to any dividend or distribution to which the above paragraph would otherwise apply, the denominator in the fraction referred to in the above formula is less than $1.00 or is a negative number, then Salomon Smith Barney Holdings may, at its option, elect to have the adjustment provided by the above paragraph not be made and in lieu of this adjustment, at maturity, each holder of the Notes will be entitled to receive an additional amount of cash equal to the product of the number of Notes held by the holder multiplied by the fair market value of the capital stock, indebtedness, assets, rights or warrants (determined, as of the date this dividend or distribution is made, by a nationally recognized independent investment banking firm retained for this purpose by Salomon Smith Barney Holdings, whose determination will be final) so distributed or issued applicable to a number of shares of Pfizer common stock equal to the Exchange Ratio. If Pfizer, after the closing date, declares a record date in respect of a distribution of cash, other than any Permitted Dividends described below, any cash distributed in consideration of fractional shares of common stock and any cash distributed in a Reorganization Event referred to below, by dividend or otherwise, to all holders of its common stock, or makes an Excess Purchase Payment, then the Exchange Ratio will be multiplied by a dilution adjustment equal to a fraction, the numerator of which will be the Then-Current Market Price of the common stock, and the denominator of which will be the Then-Current Market Price of the common stock on the record date less the amount of the distribution applicable to one share of common stock which would not be a Permitted Dividend, or, in the case of an Excess Purchase Payment, less the aggregate amount of such Excess Purchase Payment for which adjustment is being made at the time divided by the number of shares of common stock outstanding on the record date. For purposes of these adjustments: A "Permitted Dividend" is any quarterly cash dividend in respect of Pfizer common stock, other than a quarterly cash dividend that exceeds the immediately preceding quarterly cash dividend, and then only to the extent that the per share amount of this dividend results in an annualized dividend yield on the common stock in excess of 10%. An "Excess Purchase Payment" is the excess, if any, of (x) the cash and the value (as determined by a nationally recognized independent investment banking firm retained for this purpose by Salomon Smith Barney Holdings, whose determination will be final) of all other consideration paid by Pfizer with respect PS-12 13 to one share of common stock acquired in a tender offer or exchange offer by Pfizer, over (y) the Then-Current Market Price of the common stock. Notwithstanding the foregoing, in the event that, with respect to any dividend, distribution or Excess Purchase Payment to which the sixth paragraph in this section would otherwise apply, the denominator in the fraction referred to in the formula in that paragraph is less than $1.00 or is a negative number, then Salomon Smith Barney Holdings may, at its option, elect to have the adjustment provided by the sixth paragraph in this section not be made and in lieu of this adjustment, at maturity, the holders of the Notes will be entitled to receive an additional amount of cash equal to the product of the number of Notes held by the holder multiplied by the sum of the amount of cash plus the fair market value of other consideration (determined, as of the date this dividend or distribution is made, by a nationally recognized independent investment banking firm retained for this purpose by Salomon Smith Barney Holdings, whose determination will be final) so distributed or applied to the acquisition of the common stock in the tender offer or exchange offer applicable to a number of shares of Pfizer common stock equal to the Exchange Ratio. Each dilution adjustment will be effected as follows: - in the case of any dividend, distribution or issuance, at the opening of business on the Business Day next following the record date for determination of holders of Pfizer common stock entitled to receive this dividend, distribution or issuance or, if the announcement of this dividend, distribution or issuance is after this record date, at the time this dividend, distribution or issuance was announced by Pfizer; - in the case of any subdivision, split, combination or reclassification, on the effective date of the transaction; - in the case of any Excess Purchase Payment for which Pfizer announces, at or prior to the time it commences the relevant share repurchase, the repurchase price per share for shares proposed to be repurchased, on the date of the announcement; and - in the case of any other Excess Purchase Payment, on the date that the holders of the repurchased shares become entitled to payment in respect thereof. All dilution adjustments will be rounded upward or downward to the nearest 1/10,000th or, if there is not a nearest 1/10,000th, to the next lower 1/10,000th. No adjustment in the Exchange Ratio will be required unless the adjustment would require an increase or decrease of at least one percent therein, provided, however, that any adjustments which by reason of this sentence are not required to be made will be carried forward (on a percentage basis) and taken into account in any subsequent adjustment. If any announcement or declaration of a record date in respect of a dividend, distribution, issuance or repurchase requiring an adjustment as described herein is subsequently canceled by Pfizer, or this dividend, distribution, issuance or repurchase fails to receive requisite approvals or fails to occur for any other reason, then, upon the cancellation, failure of approval or failure to occur, the Exchange Ratio will be further adjusted to the Exchange Ratio which would then have been in effect had adjustment for the event not been made. If a Reorganization Event described below occurs after the occurrence of one or more events requiring an adjustment as described herein, the dilution adjustments previously applied to the Exchange Ratio will not be rescinded but will be applied to the new Exchange Ratio provided for below. The "Then-Current Market Price" of the common stock, for the purpose of applying any dilution adjustment, means the average closing price per share of common stock for the ten Trading Days immediately before this adjustment is effected or, in the case of an adjustment effected at the opening of business on the Business Day next following a record date, immediately before the earlier of the date the adjustment is effected and the related Ex-Date. The "Ex-Date" with respect to any dividend, distribution or issuance is the first date on which the shares of the common stock trade in the regular way on their principal market without the right to receive this dividend, distribution or issuance. PS-13 14 In the event of any of the following "Reorganization Events": - any consolidation or merger of Pfizer, or any surviving entity or subsequent surviving entity of Pfizer, with or into another entity, other than a merger or consolidation in which Pfizer is the continuing corporation and in which the common stock outstanding immediately before the merger or consolidation is not exchanged for cash, securities or other property of Pfizer or another issuer; - any sale, transfer, lease or conveyance to another corporation of the property of Pfizer or any successor as an entirety or substantially as an entirety; - any statutory exchange of securities of Pfizer or any successor of Pfizer with another issuer, other than in connection with a merger or acquisition; or - any liquidation, dissolution or winding up of Pfizer or any successor of Pfizer; upon a call by Salomon Smith Barney Holdings for mandatory redemption for shares of Pfizer common stock or upon exchange at the option of the holder, each holder of Notes will have the right to receive cash in an amount per $1,000 principal amount of Notes equal to the Exchange Ratio multiplied by the Transaction Value, and for purposes of determining whether the value of Pfizer common stock on the Trading Day preceding the Call Notice Date is less than the Call Price, this value will be calculated with respect to Pfizer common stock by multiplying the then-existing Exchange Ratio by the Transaction Value. If a Reorganization Event occurs, no adjustment will be made to the Exchange Ratio. The "Transaction Value" will be the sum of: 1. for any cash received in a Reorganization Event, the amount of cash received per share of common stock; 2. for any property other than cash or Marketable Securities received in a Reorganization Event, an amount equal to the market value on the date the Reorganization Event is consummated of that property received per share of common stock, as determined by a nationally recognized independent investment banking firm retained for this purpose by Salomon Smith Barney Holdings, whose determination will be final; and 3. for any Marketable Securities received in a Reorganization Event, an amount equal to the Closing Price per share of these Marketable Securities on the Trading Day immediately prior to the maturity date or Exchange Date multiplied by the number of these Marketable Securities received for each share of common stock. "Marketable Securities" are any perpetual equity securities or debt securities with a stated maturity after the maturity date, in each case that are listed on a U.S. national securities exchange or reported by the Nasdaq Stock Market. The number of shares of any equity securities constituting Marketable Securities included in the calculation of Transaction Value pursuant to clause (3) above will be adjusted if any event occurs with respect to the Marketable Securities or the issuer of the Marketable Securities between the time of the Reorganization Event and maturity that would have required an adjustment as described above, had it occurred with respect to Pfizer common stock or Pfizer. Adjustment for these subsequent events will be as nearly equivalent as practicable to the adjustments described above. The "Closing Price" of Marketable Securities on any date of determination will be the daily closing sale price, or if no closing sale price is reported, the last reported sale price of a share of Marketable Security on the applicable U.S. securities exchange. If the Marketable Securities are not quoted on a U.S. securities exchange on that date of determination, the Closing Price will be the last reported sale price as reported in the composite transactions for the principal U.S. exchange on which the Marketable Securities are listed. If the Marketable Securities are not listed on a U.S. national or regional securities exchange, the Closing Price will be the last quoted bid price for the Marketable Securities in the over-the-counter market as reported by the Nasdaq Stock Market, the National Quotation Bureau or a similar organization. PS-14 15 CALCULATION AGENT The calculation agent for the Notes will be Salomon Smith Barney Inc. All determinations made by the calculation agent will be at the sole discretion of the calculation agent and will, in the absence of manifest error, be conclusive for all purposes and binding on Salomon Smith Barney Holdings and the holders of the Notes. Because the calculation agent is an affiliate of Salomon Smith Barney Holdings, potential conflicts of interest may exist between the calculation agent and the holders of the Notes, including with respect to certain determinations and judgments that the calculation agent must make in determining amounts due to holders of the Notes. Salomon Smith Barney Inc. is obligated to carry out its duties and functions as calculation agent in good faith and using its reasonable judgment. PFIZER INC. According to Pfizer's filings with the SEC, Pfizer is a research-based, global pharmaceutical company. It discovers, develops, manufactures and markets medicines for humans and animals and many well-known consumer products. Pfizer is currently subject to the informational requirements of the Securities Exchange Act. Accordingly, Pfizer files reports (including its Annual Report on Form 10-K for the fiscal year ended December 31, 2000 and its Quarterly Report on Form 10-Q for the quarter ended April 1, 2001), proxy statements and other information with the SEC. Pfizer's registration statements, reports, proxy statements and other information may be inspected and copied at the offices of the SEC at the addresses listed under "Prospectus Summary -- Where You Can Find More Information" in the accompanying prospectus. The Notes represent obligations of Salomon Smith Barney only. Pfizer is not involved in any way in this offering and has no obligation relating to the Notes or to the holders of the Notes. PS-15 16 HISTORICAL DATA ON THE COMMON STOCK OF PFIZER INC. The common stock is quoted on the New York Stock Exchange under the symbol "PFE". The following table sets forth, for each of the quarterly periods indicated, the high and the low sale price for common stock, as reported on the New York Stock Exchange and adjusted to reflect a 2 for 1 stock split on June 30, 1997 and a 3 for 1 stock split on June 30, 1999. During the periods set forth in the table below, Pfizer has declared and paid cash dividends on its common stock quarterly.
QUARTER HIGH LOW DIVIDEND ------- ------- ------- -------- 1996 First................................................ 11.7083 10.1250 0.0500 Second............................................... 12.6250 10.7708 0.0500 Third................................................ 13.1875 11.6250 0.0500 Fourth............................................... 15.0833 13.1458 0.0500 1997 First................................................ 16.4375 13.6250 0.0567 Second............................................... 20.3333 13.8958 0.0567 Third................................................ 21.2500 17.4583 0.0567 Fourth............................................... 25.9375 20.0625 0.0567 1998 First................................................ 33.2292 24.6458 0.0633 Second............................................... 39.2083 32.5000 0.0633 Third................................................ 39.5625 31.0000 0.0633 Fourth............................................... 41.9792 29.7917 0.0633 1999 First................................................ 47.6667 37.7917 0.0733 Second............................................... 50.0000 31.7083 0.0733 Third................................................ 40.3750 32.6250 0.0800 Fourth............................................... 41.7500 32.4375 0.0800 2000 First................................................ 37.8750 30.4375 0.0900 Second............................................... 48.0000 37.7500 0.0900 Third................................................ 48.9375 39.6250 0.0900 Fourth............................................... 47.4375 42.1875 0.0900 2001 First................................................ 46.1250 35.6700 0.1100 Second............................................... 44.8700 38.9500 0.1100 Third (through July 26, 2001)........................ 44.8700 37.6000 0.1100
The closing price of Pfizer common stock on July 26, 2001 was $39.99. According to Pfizer's Quarterly Report on Form 10-Q for the quarter ended April 1, 2001, as of May 11, 2001, there were 6,312,851,420 shares of common stock outstanding. Holders of the Notes will not be entitled to any rights with respect to Pfizer common stock (including, without limitation, voting rights or rights to receive dividends or other distributions in respect thereof) prior to receiving shares of Pfizer common stock following exchange or call. PS-16 17 CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS The following is a summary of certain United States federal income tax considerations that may be relevant to a holder of a Note. This summary supplements, and should be read in conjunction with, the section entitled "United States Federal Income Tax Considerations" in the prospectus supplement. Investors should consult their own tax advisors in determining the tax consequences to them of holding Notes, including the application to their particular situation of the United States federal income tax considerations discussed below and in the prospectus supplement. TAX CHARACTERIZATION OF THE NOTES Each Note will be treated by Salomon Smith Barney Holdings for United States federal income tax purposes as a single debt instrument issued by Salomon Smith Barney Holdings that is subject to United States Treasury regulations governing contingent debt instruments (the "Contingent Debt Regulations"). Moreover, each holder, by accepting a Note, agrees to this treatment of the Note and to report all income (or loss) with respect to the Note in accordance with the Contingent Debt Regulations. The remainder of this summary assumes the treatment of each Note as a single debt instrument subject to the Contingent Debt Regulations and the holder's agreement thereto. UNITED STATES HOLDERS Taxation of Interest. A United States holder (as such term is defined in the prospectus supplement) of a Note will recognize income (or loss) on a Note in accordance with the Contingent Debt Regulations. The Contingent Debt Regulations require the application of a "noncontingent bond method" to determine accruals of income, gain, loss and deduction with respect to a contingent debt obligation. As described in more detail in the second and third succeeding paragraphs, under the noncontingent bond method, a United States holder of a Note will be required for tax purposes to include in income each year an accrual of interest at the annual computational rate of -- % (the "comparable yield"). Solely for purposes of determining the comparable yield pursuant to the Contingent Debt Regulations, a United States holder of a Note will be assumed to be entitled to receive, in respect of each Note, semi-annual payments of interest at a rate of -- %, as well as a payment of $ -- at maturity, or upon exchange or redemption (the "Assumed Exchange Amount"). The Assumed Exchange Amount is calculated as the amount required to produce the comparable yield when combined with the semi-annual payments of interest made in respect of a Note, taking into account the Note's issue price. The comparable yield and the Assumed Exchange Amount are used to determine accruals of interest FOR TAX PURPOSES ONLY and are not assurances or predictions by Salomon Smith Barney Holdings with respect to the actual yield of, or payment to be made in respect of, a Note. The comparable yield and the Assumed Exchange Amount do not necessarily represent Salomon Smith Barney Holdings's expectations regarding such yield, the amount of such payment, or whether Salomon Smith Barney Holdings will exercise its call right or any holder will exercise its exchange right. Each Note will be issued at par. However, there will be original issue discount for United States federal income tax purposes ("Tax OID") because Tax OID must be accrued at the comparable yield. Under the Tax OID rules of the Internal Revenue Code of 1986, as amended (the "Code"), and the Treasury regulations promulgated thereunder, a United States holder of a Note, whether such holder uses the cash or the accrual method of tax accounting, will be required to include as ordinary interest income the sum of the "daily portions" of Tax OID on the Note for all days during the taxable year that the United States holder owns the Note. As a result, a United States holder of a Note that employs the cash method of tax accounting will be required to include amounts in respect of Tax OID accruing on a Note in taxable income each year, even though cash payments will be made with respect to the Notes only upon Interest Payment Dates, at maturity, or upon exchange or redemption. The daily portions of Tax OID on a Note are determined by allocating to each day in any accrual period a ratable portion of the Tax OID allocable to that accrual period. In the case of an initial holder, PS-17 18 the amount of Tax OID on a Note allocable to each accrual period is determined by multiplying the "adjusted issue price" (as defined below) of a Note at the beginning of the accrual period by the comparable yield of a Note (appropriately adjusted to reflect the length of the accrual period). The "adjusted issue price" of a Note at the beginning of any accrual period will generally be the sum of its issue price and the amount of Tax OID allocable to all prior accrual periods, less the amount of any payments made in all prior accrual periods. Based upon the comparable yield, if a United States holder who employs the accrual method of tax accounting and pays taxes on a calendar year basis buys a Note at original issue for $1,000 and holds it until maturity, such holder will be required to pay taxes on the following amounts of ordinary income from the Note (in excess of accrued semi-annual interest income) for each of the following periods: $ -- in 2001; $ -- in 2002; $ -- in 2003; $ -- in 2004; $ -- in 2005; $ -- in 2006; $ -- in 2007; and $ -- in 2008. Disposition (including Exchange) of the Notes. When a United States holder sells, exchanges or otherwise disposes of a Note (including upon repayment of the Note at maturity or upon the exercise by Salomon Smith Barney Holdings of its call right or the holder of its exchange right) (a "disposition"), the United States holder's gain (or loss) on such disposition will equal the difference between the amount received by the United States holder for the Note (including, for this purpose, (a) in the case of shares of Pfizer common stock and cash in lieu of fractional shares of common stock received (the "Exchange Amount") on the Exchange Date or three Business Days after the Call Date, as the case may be, the fair market value of the shares received or (b) in the case of the Call Price, the amount of cash received) and the United States holder's tax basis in the Note. A United States holder's tax basis (i.e., adjusted cost) in a Note will be equal to the United States holder's original purchase price for such Note, plus any Tax OID accrued by the United States holder and less the amount of any payments received by the holder while holding the Note. If the call right or the exchange right is exercised, respectively, by Salomon Smith Barney Holdings or the United States holder and the Exchange Amount or the Call Price, as the case may be, exceeds the Assumed Exchange Amount, the United States holder will be required to include such excess in income as ordinary interest at maturity, or upon exchange or redemption. Alternatively, if the call right or the exchange right is exercised and the Exchange Amount or the Call Price, as the case may be, is less than the Assumed Exchange Amount, or if neither the call right nor the exchange right is exercised, the difference between the Assumed Exchange Amount and the Exchange Amount or the Call Price or the amount paid at maturity, as the case may be, will be treated as an offset to any interest otherwise includible in income by the United States holder with respect to the Note for the taxable year in which maturity, exchange or redemption occurs, but only to the extent of the amount of such includible interest. Any remaining portion of such shortfall may be recognized and deducted by the United States holder as an ordinary loss. Any gain realized by a United States holder on a disposition will be treated as ordinary interest income. Any loss realized by a United States holder on a disposition will be treated as an ordinary loss to the extent of the United States holder's Tax OID inclusions with respect to the Note up to the date of disposition. Any loss realized in excess of such amount generally will be treated as a capital loss. An individual United States holder generally will be allowed a deduction for any such ordinary loss without regard to the two-percent miscellaneous itemized deduction rule of Section 67 of the Code. Any capital loss recognized by a United States holder will be a long-term capital loss if such United States holder has held such Note for more than one year, and a short-term capital loss in other cases. A United States holder's tax basis in the shares received upon an exchange of Notes for the Exchange Amount will equal the fair market value of those shares. ERISA MATTERS The Employee Retirement Income Security Act of 1974, as amended ("ERISA"), imposes certain fiduciary requirements with respect to "employee benefit plans" (as defined in Section 3(3) of ERISA) that are subject to the fiduciary responsibility provisions of ERISA ("Plans") and on persons who are fiduciaries with respect to such Plans. Other provisions of ERISA and Section 4975 of the Internal PS-18 19 Revenue Code prohibit certain transactions involving the assets of a Plan or of a plan described in Section 4975(e)(1) of the Internal Revenue Code (including individual retirement accounts, individual retirement annuities and Keogh plans) that are subject to Section 4975 of the Internal Revenue Code (also, "Plans") and persons who have certain specified relationships to the Plan ("parties in interest" within the meaning of ERISA or "disqualified persons" within the meaning of Section 4975 of the Internal Revenue Code). Governmental plans, while not subject to the fiduciary responsibility provisions of ERISA or the provisions of Section 4975 of the Internal Revenue Code, may nevertheless be subject to local, state or other federal laws that are substantially similar to the foregoing provisions of ERISA and the Internal Revenue Code. Salomon Smith Barney Holdings, directly or through their affiliates, may be considered a party in interest or a disqualified person with respect to Plans. The purchase and holding of the Notes by a Plan (or any other entity whose assets include plan assets that is subject to the fiduciary responsibility provisions of ERISA or the prohibited transaction provisions of Section 4975 of the Internal Revenue Code) and with respect to which Salomon Smith Barney Holdings or any of its affiliates is a service provider (or otherwise is a party in interest or a disqualified person) may constitute or result in a prohibited transaction under ERISA or Section 4975 of the Internal Revenue Code, unless the Notes are acquired pursuant to and in accordance with an applicable exemption. Certain exemptions from the prohibited transaction provisions of Section 406 of ERISA and Section 4975 of the Internal Revenue Code may be applicable, depending in part on the type of Plan fiduciary making the decision to acquire the Notes and the circumstances under which such decision is made. Included among these exemptions are Prohibited Transaction Class Exemption ("PTCE") 84-14 (for certain transactions engaged in by an independent qualified professional asset manager), PTCE 91-38 (for certain transactions involving bank collective investment funds), PTCE 90-1 (for certain transactions involving insurance company pooled separate accounts), PTCE 95-60 (for certain transactions involving insurance company general accounts) and PTCE 96-23 (for certain transactions engaged in by an in-house asset manager). By its purchase of the Notes, each holder will be deemed to have represented and warranted on each day from and including the date of its purchase of the Notes through and including the date of disposition of such Notes either (i) that it is not a Plan, a government plan or an entity the assets of which are deemed to be "plan assets" under ERISA regulations, or (ii) that the acquisition, holding and disposition of the Notes by such holder does not and will not constitute a prohibited transaction under Section 406 of ERISA or Section 4975 of the Internal Revenue Code (or, in the case of a governmental plan, any substantially similar law) unless an exemption is available with respect to such transactions and the conditions of such exemption have been satisfied. Any plans or other entities whose assets include plan assets subject to ERISA, Section 4975 of the Internal Revenue Code or substantially similar federal, state or local law should consult their advisors and/or counsel. PS-19 20 EXHIBIT A OFFICIAL NOTICE OF EXCHANGE Dated: [ , ] [Must be on or after September -- , 2001] Citibank, N.A., as Salomon Smith Barney, Inc., Paying Agent as Calculation Agent 111 Wall Street, 15th Floor 390 Greenwich Street Citibank Agency & Trust New York, New York 10013 New York, NY 10005 Attn: Structured Products/Equity Derivatives Attention: Sebastian Andrieszyn Group Phone: (212) 657-9055 Phone: (212) 723-7349 Fax: (212) 825-3483 Fax: (212) 723-8732
Ladies and Gentlemen: The undersigned holder of the -- % Notes Exchangeable for the Common Stock of Pfizer Inc., Due 2008 (the "Notes") hereby irrevocably elects to exercise with respect to the principal amount of the Notes indicated below, as of the date hereof (or, if this notice is received after 11:00 a.m. on any Trading Day by either the Calculation Agent or the Paying Agent, as of the next Trading Day), provided that such day is prior to the earliest of (i) August -- , 2008, (ii) the Call Date, and (iii) in the event of a call for cash at the Call Price, the Call Notice Date, the holder's exchange right as described in the Pricing Supplement dated August -- , 2001 relating to the Notes (the "Pricing Supplement"). Capitalized terms not defined herein have the meanings given to such terms in the Pricing Supplement. Please date and acknowledge receipt of this notice in the place provided below on the date of receipt, and fax a copy to the fax number indicated, whereupon Salomon Smith Barney Holdings shall cause our affiliate, Salomon Smith Barney Inc., to deliver the required number of shares to the Paying Agent through the facilities of DTC; the Paying Agent will in turn be obligated to deliver the required number of shares three Business Days after the Exchange Date in accordance with the delivery instructions set forth below, as long as the Paying Agent has received delivery of the Notes being exchanged on the Exchange Date. Very truly yours, [Name of Holder] By: -------------------------------------- [Title] [Fax No.] $ ------------------------------------- Principal Amount of Notes being Exchanged [must be $1,000 or integral multiple thereof] 21 Delivery Instructions for the shares of the Common Stock of Pfizer Inc.: --------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- Receipt of the above Official Notice of Exchange is hereby acknowledged: SALOMON SMITH BARNEY INC., as Calculation Agent CITIBANK, N.A., as Paying Agent. By: CITIBANK, N.A., as Paying Agent. By: ------------------------------------------------------ Name: Title: Date and Time of Acknowledgement: ------------------------------------------ 22 ------------------------------------------------------ ------------------------------------------------------ YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED OR INCORPORATED BY REFERENCE IN THIS PRICING SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS SUPPLEMENT AND PROSPECTUS. WE HAVE NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH DIFFERENT INFORMATION. WE ARE NOT MAKING AN OFFER OF THESE SECURITIES IN ANY STATE WHERE THE OFFER IS NOT PERMITTED. YOU SHOULD NOT ASSUME THAT THE INFORMATION CONTAINED OR INCORPORATED BY REFERENCE IN THIS PRICING SUPPLEMENT IS ACCURATE AS OF ANY DATE OTHER THAN THE DATE ON THE FRONT OF THE DOCUMENT. ------------------ TABLE OF CONTENTS
PAGE ----- PRICING SUPPLEMENT Summary Information -- Q&A............. PS-2 Incorporation of Certain Documents by Reference............................ PS-4 Risk Factors Relating to the Notes..... PS-5 Description of the Notes............... PS-9 Pfizer Inc. ........................... PS-15 Historical Data on the Common Stock of Pfizer Inc. ......................... PS-16 Certain United States Federal Income Tax Considerations................... PS-17 ERISA Matters.......................... PS-18 PROSPECTUS SUPPLEMENT Risk Factors........................... S-3 Important Currency Information......... S-6 Description of the Notes............... S-7 Unites States Federal Income Tax Considerations....................... S-31 Plan of Distribution................... S-38 Legal Matters.......................... S-39 PROSPECTUS Prospectus Summary..................... 2 Forward-Looking Statements............. 6 Salomon Smith Barney Holdings Inc...... 7 Use of Proceeds and Hedging............ 8 Ratio of Earnings to Fixed Charges..... 9 European Monetary Union................ 10 Description of Debt Securities......... 11 Description of Index Warrants.......... 18 Book-Entry Procedures and Settlement... 21 Limitations on Issuances in Bearer Form................................. 22 Plan of Distribution................... 23 ERISA Matters.......................... 25 Legal Matters.......................... 25 Experts................................ 25
------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ SALOMON SMITH BARNEY HOLDINGS INC. MEDIUM-TERM NOTES $ -- -- % NOTES EXCHANGEABLE FOR THE COMMON STOCK OF PFIZER INC. DUE AUGUST -- , 2008 ($1,000 PRINCIPAL AMOUNT PER NOTE) ------------ PRICING SUPPLEMENT AUGUST --, 2001 (INCLUDING PROSPECTUS SUPPLEMENT DATED MARCH 1, 2001 AND PROSPECTUS DATED FEBRUARY 23, 2001) ------------ SALOMON SMITH BARNEY ------------------------------------------------------ ------------------------------------------------------